Payment cuts, parity decisions, and new compliance rules are coming for ophthalmic ASCs.

At #AAO2025, Mike Romansky, JD, broke down what centers need to prepare for — including a 4.7% cataract rate drop and new PA requirements.

Full recap:
https://ow.ly/N3eV50Xuy17

#Ophthalmology

At #AAO2025, ASC leaders shared practical ways to boost efficiency — from precision turnover and smarter tech integration to “all hands on deck” teamwork.

Full insights:
https://ow.ly/9uwx50XuxMF

#Ophthalmology #ASC #SurgeryCenters

Still reminiscing on #AAO2025 👁️

Our CU Anschutz Ophthalmology team had an incredible time connecting, sharing research, and celebrating advances in vision science.

#CUAnschutz #Ophthalmology #AAO #VisionResearch

GLP-1 Drugs Tied to Lower Risk of Legal Blindness in People With Diabetes Retrospective study finds no link with higher risk of rare eye disease, contrary to prior work

"People read headlines, and they get scared." -- Praveena Gupta, OD, PhD, of @utmbhealth.bsky.social, on new research linking #GLP-1 agents with a lower risk of legal blindness. #AAO2025
www.medpagetoday.com/meetingcover...

GLP-1 RA Use Linked to Retinal Detachment and Ischemic Optic Neuropathy  - Ophthalmology Advisor Investigators reviewed ocular side effects of semaglutide use from a global population-based study across 180 countries.

#AAO2025: Semaglutide, a glucagon-like peptide-1 receptor agonist (#GLP1RA), can elevate some patients’ likelihood of developing ischemic optic neuropathy (#ION) and retinal detachment (#RD) compared with #Tirzepatide.

Read more: https://bit.ly/3JfF9bK

#MedSky #Ophthalmology

Dry Eye Therapy With TRPM8 Agonist May Lead To Meaningful Long-Term Improvement - Ophthalmology Advisor In 2 phase 3 studies, acoltremon 0.003% met primary endpoints, demonstrating statistically significant tear production at day 14.

#AAO2025: A novel topical agent may offer rapid and sustained relief for patients with #DryEyeDisease, according to research presented at the American Academy of Ophthalmology 2025 annual meeting held in Orlando, FL, October 18 to 20.

Read more: https://bit.ly/3WiIv0B

#Ophthalmology #MedSky

Lots of news out of four major medical conferences this week– here are some of the top stories from #IDWeek2025, #ESMO2025, #CHEST2025 and #AAO2025 in a special edition of our headline round-up.

For more of our meeting coverage, check out: https://www.medpagetoday.com/meetingcoverage?trw=no

Retinal Vein Occlusion Subtypes Can Be Treated With High Dose Aflibercept - Ophthalmology Advisor Researchers compared the use of aflibercept 8 mg and 2 mg in patients with various retinal vein occlusion subtypes.

#AAO2025: Treatment with high dose #Aflibercept 8 mg can lead to similar #VisualOutcomes with fewer injections for patients with various #RetinalVeinOcclusion (RVO) subtypes.

Read more: https://bit.ly/4o3qTSp

#Ophthalmology #EyeSky #RVO #MedSky

IGF-1R Antibody Reduces Thyroid Eye Disease Signs, Improves Quality of Life - Ophthalmology Advisor Researchers assessed the quality of life measures of patients with thyroid eye disease treated with Veligrotug, a full antagonist humanized mAb to IGF-1R.

#AAO2025: Treatment with an intravenously delivered, anti-insulin-like growth factor-1 receptor (IGF-1R) antibody can reduce signs of thyroid eye disease (#TED) and improve quality of life.

Read here: https://bit.ly/3LrozWR

#Ophthalmology #IGF1R #ThyroidEyeDisease

Retinopathy of Prematurity Anti-VEGF Monotherapy Outcomes Remain Strong Long Term - Ophthalmology Advisor Investigators evaluated long-term outcomes for ROP patients with persistent avascular retina initially treated with anti-VEGF injections without laser therapy.

#AAO2025: Even with persistent areas of avascular retina (#PAR) after #AntiVEGF monotherapy, outcomes for patients with #RetinopathyOfPrematurity remain favorable.

Read more: https://bit.ly/4ho41dU

#Ophthalmology #MedSky #EyeSky

Trial Participants’ Vision Worsened 3 Years After Diabetic Retinopathy Treatment Study - Ophthalmology Advisor Investigators reviewed the long-term outcomes of patients who completed the PANORAMA clinical trial and have since sought standard clinical care.

#AAO2025: Long-term follow-up of patients with nonproliferative diabetic retinopathy (#NPDR) enrolled in the #VOYAGE study reveals a concerning pattern of disease progression following completion of #ClinicalTrial care.

Read more: https://bit.ly/4oCLVr6

#Ophthalmology #Retina

#AAO2025: Explainable artificial intelligence (#XAI) can identify clinically significant diabetic retinal neurodegeneration (#DRN) on optical coherence tomography (#OCT) images. Presented at the American Academy of Ophthalmology (AAO) 2025 meeting

Read more: https://bit.ly/4oCKmcI

#MedTech #AI

#AAO2025: Despite years of safety campaigns and advances in toy design, the rate of toy-related #OcularInjuries (#TOIs) among children in the U.S. has remained largely unchanged for the past 2 decades

Read more: https://bit.ly/3LoWzTN

#Ophthalmology #MedSky #EyeSafety

MicroRNA Eye Drop Improves Symptoms and Signs of Dry Eye Disease and Corneal Repair - Ophthalmology Advisor Investigators evaluated the application of a microRNA therapy for both corneal repair and dry eye disease.

#AAO2025: A novel #microRNA eye drop therapeutic option to manage either #DryEyeDisease (DED) or #CornealRepair, or both, may be on the horizon as demonstrated by 2 #ClinicalTrial results.

Read more: https://bit.ly/47m7WmQ

#Ophthalmology #MedSky #EyeSky

Congratulations to Michael Puente, MD, recipient of the 2025 Artemis Award from American Academy of Ophthalmology!

This honor recognizes a Young Ophthalmologist whose compassion & dedication to patients exemplify the spirit of Artemis — protector of the vulnerable. 🎉

#AAO2025 #Ophthalmology

GLP-1 Drugs Tied to Lower Risk of Legal Blindness in People With Diabetes Retrospective study finds no link with higher risk of rare eye disease, contrary to prior work

A retrospective cohort study presented at #AAO2025 linked GLP-1 receptor agonists to a lower risk of legal blindness in patients with type 2 diabetes and risk for cardiovascular disease.

Read more at:
www.medpagetoday.com/meetingcoverage/aao/1180...

Pickleball-Related Ocular Injuries On The Rise, Experts Champion Protective Eye Wear - Ophthalmology Advisor Researchers parsed the risks and types of ocular injuries associated with pickleball.

#AAO2025: Researchers parsed the risks and types of ocular injuries associated with pickleball. Presented at the American Academy of Ophthalmology (AAO) 2025 conference

Read more: https://bit.ly/4o1iSNQ

#Ophthalmology #MedSky #EyeSky #OcularInjuries #Pickleball

#AAO2025: With a single dose, bioerodible #Vorolanib intravitreal insert may preserve vision and benefit anatomic structures, lengthening treatment duration. Presented at the American Academy of Ophthalmology annual meeting

Read more: https://bit.ly/4hmUZhm

#Ophthalmology #ClinicalTrial #EYP1901

Glaucoma Risk Increased for Patients Using SGLT-2 Inhibitors, GLP-1 RA - Ophthalmology Advisor Researchers evaluated the changes to glaucoma risk for patients using hypoglycemic agents to manage diabetes.

#AAO2025: Certain classes of #HypoglycemicAgents may carry an increased risk for developing #Glaucoma. Presented at American Academy of Ophthalmology.

This @stonybrooku.bsky.social - study was presented by Millen S. Khangura and team.

Read more: https://bit.ly/4hFZKmt

#Ophthalmology #MedSky

Proud to support hands-on training at #AAO2025. Our team prepped 25 pre-stripped, pre-stamped DMEK grafts for corneal wet labs—continuing our annual donation of ~25–30 corneas so surgeons sharpen skills and patients benefit. Thanks Braedon, Helena, Wesley, Recovery & Research. #SeeTheGift

Adalimumab Bests Conventional Therapy For Steroid Sparing in Uveitis But long-term effects aren't known, and insurers tend to balk at front-line cost, experts say

Adalimumab (Humira) was more effective than conventional immunosuppressive drugs at lowering or eliminating the need for corticosteroid use in patients with noninfectious uveitis, according to ADVISE trial data. #AAO2025
https://www.medpagetoday.com/meetingcoverage/aao/118022

Travoprost Intracameral Implant Reduces Glaucoma Treatment Burden Through 36 Months - Ophthalmology Advisor Researchers compared the medication burden of an intracameral implant and a topical IOP-lowering drop.

#AAO2025: A sustained-release #Travoprost intracameral implant significantly reduced the need for topical #IOP–lowering medications compared with timolol through 36 months in patients with open-angle #Glaucoma or #OcularHypertension. Presented at AAO 2025.

Read more: https://bit.ly/3L1ELy0

#MedSky

Early Onset Cataract, Retinal Detachment Risk Higher With Retinitis Pigmentosa - Ophthalmology Advisor Investigators conducted a large-scale retrospective cohort study of the prevalence and age of onset of retinal detachment and cataracts among patients with retinitis pigmentosa.

#AAO2025: Investigators conducted a large-scale retrospective cohort study of the prevalence and age of onset of #RetinalDetachment and #Cataracts among patients with #RetinitisPigmentosa. Presented at AAO 2025.

Read here: https://bit.ly/4oxMZwo

#Ophthalmology #MedSky #EyeSky

Foselutoclax Delivers Durable Vision Benefits in Diabetic Macular Edema - Ophthalmology Advisor Presenters at the AAO discussed phase 2 clinical trial results evaluating the safety and efficacy of foselutoclax (UBX1325) compared with aflibercept in diabetic macular edema.

#AAO2025: #Foselutoclax can improve best-corrected visual acuities in patients with #DiabeticMacularEdema and #VisualAcuity deficits, despite prior #AntiVEGF treatment. Presented at AAO 2025 by David Eichenbaum, MD, of Retina Vitreous Associates of Florida.

Read more ➡️: bit.ly/4nd34Xa

American Academy of Ophthalmology Annual Meeting Original Article | OCT 20, 2025 | NEJM.org Subretinal Photovoltaic Implant to Restore Vision in Geographic Atrophy Due to AMD Figure 2. Retinal Imaging before and after Implantation. NEJM identity sits at the bottom.

In persons with geographic atrophy due to age-related macular degeneration, a neurostimulation system composed of glasses, a processor, and a subretinal implant restored central vision and significantly improved visual acuity. Full PRIMAvera study: nej.md/3KP9Jta

#AAO2025

Harry Potter was the theme of this year's Who Wants to Be a SuperTech? quiz-style session that is an annual meeting favorite of the AAOP’s Clinical Teams Program. Which team won the AAOP Super Tech TriWizard Tournament?

Find out here: www.aao.org/eyenet/acade...

#Ophthalmology #AAO #AAO2025

Fun seeing these old faces from Chapel Hill last night! Four generations of chief residents at UNC Ophthalmology. Brought back memories from our time living in North Carolina for Rebecca's residency. In Orlando for the AAO conference (American Academy of Ophthalmology). #AAO2025 #rgli👩🏻‍⚕️

If you are attending the American Academy of Ophthalmology meeting in Orlando stop by our Booth #1202 and say hi!
#Ophthalmology #AAO #AAO2025

Fortrea is ready to ready to kick off #AAO2025 in Orlando! Our team of ophthalmology experts is onsite and looking forward to connecting on the exhibit floor. You will be able to find us all week at booth 854.
#Ophthalmology #ClinicalTrials #FortreaExperts #PatientCentricity

Article titled, "Impact of the Diabetes Endothelial Keratoplasty Study" by Kathryn A. Colby, MD, PhD, and Andrea L. Blitzer, MD. Article discusses a study on corneal transplants and diabetes.

💬 Invited Commentary: The DEKS trial showed that donor diabetes did not compromise 1-year DMEK graft success or endothelial cell loss, supporting broader use of diabetic donor tissue to help address corneal tissue shortages.

#AAO2025

ja.ma/4oqMK6d